Stockreport

Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20...

Celldex Therapeutics, Inc.  (CLDX) 
Last celldex therapeutics, inc. earnings: 11/12 08:01 am Check Earnings Report
US:NASDAQ Investor Relations: ir.celldex.com
PDF First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary a [Read more]